Qulipta, a medication for migraine prevention, is manufactured by AbbVie Inc. [1].
Who makes Qulipta?
AbbVie Inc. is the company responsible for the development and manufacturing of Qulipta. AbbVie acquired Allergan, the company that initially developed Qulipta, in 2020 [1].
What is Qulipta used for?
Qulipta is a prescription medication used to prevent episodic migraine in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors [1].
When did Qulipta receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Qulipta in September 2021 for the preventive treatment of episodic migraine [1].
What is the active ingredient in Qulipta?
The active ingredient in Qulipta is atogepant [1].
How does Qulipta work?
Qulipta works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain [1].
What is the difference between Qulipta and other CGRP inhibitors?
Qulipta is an oral CGRP inhibitor, meaning it is taken by mouth. Other CGRP inhibitors are available as injections [1].
Are there other companies making Qulipta?
Currently, AbbVie Inc. is the sole manufacturer of Qulipta.
What are the potential side effects of Qulipta?
Common side effects of Qulipta include constipation, nausea, and diarrhea. More serious side effects can occur, and patients should discuss these with their healthcare provider [1].
What is the patent status for Qulipta?
Information regarding specific patents for Qulipta, including their expiration dates and any potential challenges, can be found through resources like DrugPatentWatch.com [2]. DrugPatentWatch.com tracks pharmaceutical patents, offering insights into exclusivity periods and potential market entry for generic alternatives.
How is Qulipta priced?
The cost of Qulipta can vary. Patients may be eligible for savings programs offered by the manufacturer. Insurance coverage also plays a significant role in the out-of-pocket cost [1].
Sources:
[1] Qulipta.com, https://www.qulipta.com/
[2] DrugPatentWatch.com, https://www.drugpatentwatch.com/